Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of mecasermin rinfabate.
Expert Opin Biol Ther. 2006 May; 6(5):533-8.EO

Abstract

There has been interest in using recombinant human (rh) insulin-like growth factor (IGF)-I (rhIGF-I) to treat short stature, either alone or in combination with its binding protein (insulin-like growth factor binding protein [IGFBP]-3). IGF-I has been shown to increase growth velocity in children with IGF deficiency, either as a result of growth hormone insensitivity syndrome (GHIS) or IGF gene deletion. However, there have been adverse events, particularly hypoglycaemia, reported with administration of unbound rhIGF-I. In addition, the serum half-life of unbound rhIGF-I is shorter when administered to patients with GHIS, who have low serum concentrations of its binding proteins IGFBP-3 and acid-labile subunit (ALS), than when administered to normal volunteers or to the patient with an IGF-I gene deletion (who had normal levels of IGFBP-3). iPlex (mecasermin rinfabate), an equimolar mixture of IGF-I and its binding protein IGFBP-3, was developed to prolong the half-life and to counteract acute adverse events (particularly hypoglycaemia) associated with administration of IGF-I. Although there are no published data on the efficacy of mecasermin rinfabate in treating growth disorders, it does appear that mecasermin rinfabate has a longer half-life in patients with GHIS than unbound IGF-I, and fewer reports of adverse events (including hypoglycaemia) when administered to patients with diabetes.

Authors+Show Affiliations

University of Arkansas for Medical Sciences, Arkansas Children's Hospital, Little Rock, AR 72202-3591, USA. KempStephenF@uams.eduNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16610982

Citation

Kemp, Stephen F., et al. "Efficacy and Safety of Mecasermin Rinfabate." Expert Opinion On Biological Therapy, vol. 6, no. 5, 2006, pp. 533-8.
Kemp SF, Fowlkes JL, Thrailkill KM. Efficacy and safety of mecasermin rinfabate. Expert Opin Biol Ther. 2006;6(5):533-8.
Kemp, S. F., Fowlkes, J. L., & Thrailkill, K. M. (2006). Efficacy and safety of mecasermin rinfabate. Expert Opinion On Biological Therapy, 6(5), 533-8.
Kemp SF, Fowlkes JL, Thrailkill KM. Efficacy and Safety of Mecasermin Rinfabate. Expert Opin Biol Ther. 2006;6(5):533-8. PubMed PMID: 16610982.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and safety of mecasermin rinfabate. AU - Kemp,Stephen F, AU - Fowlkes,John L, AU - Thrailkill,Kathryn M, PY - 2006/4/14/pubmed PY - 2007/10/3/medline PY - 2006/4/14/entrez SP - 533 EP - 8 JF - Expert opinion on biological therapy JO - Expert Opin Biol Ther VL - 6 IS - 5 N2 - There has been interest in using recombinant human (rh) insulin-like growth factor (IGF)-I (rhIGF-I) to treat short stature, either alone or in combination with its binding protein (insulin-like growth factor binding protein [IGFBP]-3). IGF-I has been shown to increase growth velocity in children with IGF deficiency, either as a result of growth hormone insensitivity syndrome (GHIS) or IGF gene deletion. However, there have been adverse events, particularly hypoglycaemia, reported with administration of unbound rhIGF-I. In addition, the serum half-life of unbound rhIGF-I is shorter when administered to patients with GHIS, who have low serum concentrations of its binding proteins IGFBP-3 and acid-labile subunit (ALS), than when administered to normal volunteers or to the patient with an IGF-I gene deletion (who had normal levels of IGFBP-3). iPlex (mecasermin rinfabate), an equimolar mixture of IGF-I and its binding protein IGFBP-3, was developed to prolong the half-life and to counteract acute adverse events (particularly hypoglycaemia) associated with administration of IGF-I. Although there are no published data on the efficacy of mecasermin rinfabate in treating growth disorders, it does appear that mecasermin rinfabate has a longer half-life in patients with GHIS than unbound IGF-I, and fewer reports of adverse events (including hypoglycaemia) when administered to patients with diabetes. SN - 1744-7682 UR - https://www.unboundmedicine.com/medline/citation/16610982/Efficacy_and_safety_of_mecasermin_rinfabate_ L2 - https://www.tandfonline.com/doi/full/10.1517/14712598.6.5.533 DB - PRIME DP - Unbound Medicine ER -